In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...

Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

UNITY / MARCO ISLAND, Fla. - Robert "Bob" Elwood Knowles passed peacefully at his home in Unity, Saturday Jan. 11, 2025. Bob ...

A new predictive tool called the Florey Dementia Index (FDI) shows promising accuracy in forecasting the onset of mild ...

( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

Awards Sponsored by RAK Chamber of Commerce and Industry Recognize Innovation in 18 MENA Nations Fairfax / Virginia ...

One particular metabolite, AMK, has shown great potential in improving memory and safeguarding against cognitive ...